Insulet Corporation has been a subject of keen interest for various investment entities and analysts. The stock saw increased positions by institutional investors such as Marshall Wace LLP, Norges Bank, Quantbot Technologies LP, and more. The company's stock has also seen acquistions by noteworthy stakeholders like Prudential Financial Inc. and Vanguard Group Inc. Equipped with their FDA 510(k) cleared Omnipod® 5 Algorithm enhancements, the business presents promising potential, transforming insulin delivery and simplifying the pod experience. The upgraded Omnipod 5 is predicted to bring a significant impact on Insulet's performance. As per TD Cowen, the stock price target remains a solid $379 following the FDA clearance. Canaccord Genuity even raised the price target to $399 while maintaining a buy rating. While earning results have been on the positive side with Q2 Revenue surging by 32.9% to $649M, there have been unexpected fluctuations and stock drops including on investor day. Despite a few hurdles, Insulet continues to be recognized as a strong growth and momentum stock in the bio-tech market.
Insulet Corporation PODD News Analytics from Thu, 08 May 2025 07:00:00 GMT to Fri, 05 Dec 2025 15:53:03 GMT -
Rating 8
- Innovation 8
- Information 7
- Rumor -5
